# Safety, Tolerability, Pharmacokinetics,Pharmacodynamics Study of LAPS-Exendin in Subjects of Type 2 Diabetes Mellitus

> **NCT01452451** · PHASE2 · COMPLETED · sponsor: **Hanmi Pharmaceutical Company Limited** · enrollment: 72 (actual)

## Conditions studied

- Diabetes Mellitus

## Interventions

- **DRUG:** HM11260C
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01452451
- **Lead sponsor:** Hanmi Pharmaceutical Company Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-12
- **Primary completion:** 2013-06
- **Final completion:** —
- **Target enrollment:** 72 (ACTUAL)
- **Last updated:** 2016-08-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01452451

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01452451, "Safety, Tolerability, Pharmacokinetics,Pharmacodynamics Study of LAPS-Exendin in Subjects of Type 2 Diabetes Mellitus". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT01452451. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*